Immunotherapy against lung cancer does not need to compromise the outcomes of COVID-19

Jiadi Gan; Jiaxuan Wu; Huohuo Zhang; Dan Liu; Weimin Li

doi:10.1002/mco2.451

PDF

MedComm ›› 2024, Vol. 5 ›› Issue (1) : e451. DOI: 10.1002/mco2.451

LETTER

Immunotherapy against lung cancer does not need to compromise the outcomes of COVID-19

Author information +

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Jiadi Gan, Jiaxuan Wu, Huohuo Zhang, Dan Liu, Weimin Li. Immunotherapy against lung cancer does not need to compromise the outcomes of COVID-19. MedComm, 2024, 5(1): e451 https://doi.org/10.1002/mco2.451

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	World Health Organization. WHO coronavirus (COVID-19) dashboard. Accessed September 27, 2023. https://covid19.who.int/

[2]	Abbasi J. What to know about EG.5, the latest SARS-CoV-2 “Variant of Interest”. JAMA. 2023;b330(10):900-901.

[3]	Yaddanapudi LN. Comorbidities and COVID-19. J Anaesthesiol Clin Pharmacol. 2020;36(1):S18-S20.Suppl.

[4]	Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31(7):894-901.

[5]	Tan Y, Tang F. SARS-CoV-2-mediated immune system activation and potential application in immunotherapy. Med Res Rev. 2021;41(2):1167-1194.

[6]	National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Accessed October 28, 2022. https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf

RIGHTS & PERMISSIONS

2023 2023 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.